Old Web
English
Sign In
Acemap
>
authorDetail
>
Louise J. Rushbrooke
Louise J. Rushbrooke
Kallikrein
Retinal
Medicine
Anatomy
Pathology
3
Papers
22
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study
2019
The Journal of Allergy and Clinical Immunology
Sally L. Hampton
Gian Marco De Donatis
Nivetha Murugesan
Louise J. Rushbrooke
Lily Li
Edward Duckworth
Michael D. Smith
Rachel M. Morten
Andreas Maetzel
Christopher M. Yea
Edward P. Feener
Show All
Source
Cite
Save
Citations (2)
A novel oral plasma kallikrein (PKal) inhibitor KV123833 blocks VEGF-mediated retinal vascular hyperpermeability in a murine model of retinal edema
2018
Investigative Ophthalmology & Visual Science
Nivetha Murugesan
Allen C. Clermont
Louise J. Rushbrooke
Peter A. Robson
Robrecht Thoonen
Stephen J Pethen
Sally L. Hampton
Edward P. Feener
Show All
Source
Cite
Save
Citations (2)
Plasma Kallikrein Mediates Vascular Endothelial Growth Factor–Induced Retinal Dysfunction and Thickening
2016
Investigative Ophthalmology & Visual Science
Allen C. Clermont
Nivetha Murugesan
Qunfang Zhou
Takeshi Kita
Peter A. Robson
Louise J. Rushbrooke
D. Michael Evans
Lloyd Paul Aiello
Edward P. Feener
Show All
Source
Cite
Save
Citations (18)
1